Avatrombopag (Doptelet®). HTA ID: 20006
Avatrombopag is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 11/02/2020 |
| Rapid review completed | 02/04/2020 |
| Rapid Review outcome | A full HTA is not recommended. The NCPE recommends that avatrombopag be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement; September 2020